# Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

> **NCT02286687** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 150 (estimated)

## Conditions studied

- Advanced Malignant Neoplasm
- ATM Gene Mutation
- BRCA1 Gene Mutation
- BRCA2 Gene Mutation
- Metastatic Malignant Neoplasm
- PALB2 Gene Mutation
- Recurrent Malignant Neoplasm
- Refractory Malignant Neoplasm

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT02286687
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-12-22
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02286687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02286687, "Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02286687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*